FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> FDA | FDA news | Vioxx | drug safety | PDUFA | Janet Woodcock

FDA taps new-yet-old drug chief

Tools

As the ink was still drying on the new drug-safety bill, FDA shuffled its management, bringing back Janet Woodcock as director of the Center for Drug Evaluation and Research. The previous director, Steven Glason, will take over as acting Surgeon General October 1.

Woodcock held the reins at CDER for more than 10 years before becoming deputy commissioner. She'll need that experience to take on the safety overhaul ordered by Congress--which involves a bigger budget, more power, and lots more responsibility to seek out unsafe drugs before a Vioxx-like disaster strikes.

- see the FDA commissioner's statement
- read this piece from The Wall Street Journal (sub. req.)

Related Articles:
House overhauls, passes PDUFA. Report
Drug safety system 'broken'. Report
IOM slams FDA, calls for major reforms. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about PDUFA   Janet Woodcock   Steven Glason   CDER   FDA   FDA news   Vioxx   drug safety